# US 2001/0025055 A1 · New guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025055 A1
- Document ID: US20010025055A1
- Status: Published application
- Kind: A1
- Application number: 09/815,992
- Filed: 2001-03-23
- Published: 2001-09-27
- Earliest claimed: 1996-05-24
- Inventors: Eberhard Amtmann; Norbert Frank; Gerhard Sauer; Gerhard Schilling
- Web page: https://patentgrep.com/patent/US20010025055A1

## CPC

- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- C07C 281/18: the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
- C07C 2602/28: Hydrogenated naphthalenes
- C07C 2603/24: Anthracenes; Hydrogenated anthracenes
- C07C 2603/74: Adamantanes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention concerns new guanidine derivatives of formula (I), methods of preparing them and their use in drugs containing such compounds. 1

## Claims

### Claim 1

Compounds of general formula I: 5
wherein
X denotes R1, —NHR1, —NH—NH—CHR1R2, —NH—N═CR1R2, 6
R1 and R2 independently of each other denote hydrogen, a straight-chained or branched C3-20-alkyl, C3-20-cycloalkyl group, an adamantyl, norbornyl, tricyclodecyl, benzyl, furyl, pyridyl, indolyl, quinolyl, anthracenyl, phenanthryl, perinaphthyl or quinuclidinyl group, whilst the above-mentioned straight-chained or branched C3-20-alkyl group may be substituted by a hydroxy, C1-4-alkoxy group, a halogen atom or an amino group and the above-mentioned C3-20-cycloalkyl group may be substituted by a hydroxy, C1-4-alkoxy, C1-4-alkyl group or by a halogen atom or an amino group, and wherein, if X denotes —NH—N═CR1R2, only one of the substituents R1 and R2 can represent hydrogen,
optionally in the form of the individual optical isomers, mixtures of the individual isomers or racemates, tautomers such as geometrical isomers e.g. cis/trans isomers, as well as in the form of the free bases or corresponding acid addition salts with pharmacologically acceptable acids.

### Claim 2 (depends on 1)

Compounds of general formula I according to claim 1, characterised in that
X denotes —NH—NH—CH2R1 and —NH—N═CHR1
R1 denotes C8-20-alkyl, either branched or unbranched.

### Claim 3 (depends on 1)

Compounds of general formula I according to claim 1, characterised in that
X denotes —NH—NH—CH2R1 and —NH—N═CHR1, and
R1 denotes an unbranched decyl group.

### Claim 4 (depends on 1)

Pharmaceutical preparation, characterised in that it contains a compound according to claim 1 and the acid addition salts thereof with pharmaceutically acceptable acids together with conventional excipients and carriers.

### Claim 5 (depends on 2, 4)

Pharmaceutical preparation according to claim 4, characterised in that it contains a compound according to claim 2 and the acid addition salts thereof with pharmacologically acceptable acids together with conventional excipients and carriers.

### Claim 6 (depends on 3, 4)

Pharmaceutical preparation according to claim 4, characterised in that it contains a compound according to claim 3 and the acid addition salts thereof with pharmacologically acceptable acids together with conventional excipients and carriers.

### Claim 7 (depends on 1, 2, 3)

Use of compounds according to one of claims 1 to 3 for preparing a drug for inhibiting sphingomyelinase.

### Claim 8 (depends on 7)

Use of compounds according to claim 7 for preparing a drug for inhibiting neutral sphingomyelinase.

### Claim 9 (depends on 7, 8)

Use of compounds according to one of claims 7 and 8 for preparing a drug for the treatment of inflammatory diseases and autoimmune diseases.

### Claim 10 (depends on 9)

Use of compounds according to claim 9 for preparing a drug for treating rheumatoid arthritis, seronegative arthropathy, emphysema bronchitis, chronic obstructive pulmonary disease(COPD), osteoarthrits, inflammatory bowel disease, Crohn's disease, systemic lupus erythematosis, iridocyclitis, uveitis, optic neuritis, idiopathic pulmonary fibrosis, systemic vasculitis/Wegner's granulomatosis, sarcoidosis and orchitis/vasectomy reversal procedures.

### Claim 11 (depends on 7, 8)

Use of compounds according to one of claims 7 and 8 for preparing a drug for the treatment of cardiovascular diseases.

### Claim 12 (depends on 11)

Use of compounds according to claim 11 for preparing a drug for the treatment of cardiac stun syndrome, myocardial infarction, congestive heart failure and arteriosclerosis.

### Claim 13 (depends on 7, 8)

Use of compounds according to one of claims 7 and 8 for preparing a drug for treating infectious diseases.

### Claim 14 (depends on 13)

Use of compounds according to claim 13 for preparing a drug for the treatment of papilloma virus infections, herpes virus infections, HIV infection/HIV neuropathology, meningitis, hepatitis, septic arthritis, peritonitis, pneumonia, bronchitis, epiglottitis, E. coli 0157:H7 infection, haemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, malaria, Dengue haemorrhagic fever, leishmaniasis, leprosy, toxic shock syndrome, Streptococcal myositis, gas gangrene, mycobacterium tuberculosis infections, mycobacterium avium intracellular infections, pneumocystosis, pelvic inflammatory disease, orchitis/epidydimitis, legionella, lyme disease, influenza A virus infections, infections caused by Epstein-Barr virus, viral associated haemaphagocytic syndrome, viral encephalitis/aseptic meningitis.

### Claim 15 (depends on 7, 8)

Use of compounds according to one of claims 7 and 8 for preparing a drug for treating malignant diseases and for tumour therapy.

### Claim 16 (depends on 15)

Use of compounds according to claim 15 for preparing a drug for tumour therapy in conjunction with chemotherapy, radiotherapy and cytokine treatment, such as, for example: TNF-α treatment, for treating sarcomas, carcinomas, leukaemias
ALL
AML
CML
CLL
small cell and non-small cell bronchial carcinoma
breast cancer
squamous cell carcinoma
Hodgkin's disease, non-Hodgkin's lymphoma
multiple melanoma
Kaposi's sarcoma
colorectal carcinoma
nasopharyngeal carcinoma
malignant histiocytosis
paraneoplastic syndrome/hypercalcaemia of malignancy.

### Claim 17 (depends on 2)

Process for preparing compounds according to claim 2, characterised in that an aldehyde or a ketone of general formula R1CHO or R1C(O)R2, wherein R1 and/or R2 have the meanings given in claim 2, is reacted with an aminoguanidine and optionally the imine function resulting from this reaction is reduced by methods known per se in the presence of a hydrogenation catalyst under elevated hydrogen pressure, the reaction product is isolated and the corresponding acid addition salt is optionally formed with a pharmacologically acceptable acid.
